No Data
H.C. Wainwright Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $15
Buy Recommendation for Werewolf Therapeutics: Promising Developments in WTX-330 Clinical Trials
Werewolf Therapeutics | 10-Q: Quarterly report
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Werewolf Therapeutics Believes Existing Cash and Cash Equivalents Will Be Sufficient to Fund Operational Expenses and Cap Expenditure Requirements Through at Least the 2Q of 2026 >HOWL
Express News | Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
No Data
No Data